medicine-news-1/sexist-jokes-favor-the-mental-mechanisms-that-justify-violence-against-women-50661-1/;+scheduling.html/

Breaking Biology Technology:Successful Stem Cell Therapy for Treatment of Eye Disease 2 Successful Stem Cell Therapy for Treatment of Eye Disease 3 Successful Stem Cell Therapy for Treatment of Eye Disease 4 Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2 Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 2 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 3

[0] Successful Stem Cell Therapy for Treatment of Eye Disease [0] Lotus Pharmaceuticals, Inc. Appoints OTC Division Head [0] Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors [0] Quest Diagnostics Declares Quarterly Cash Dividend

Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2 ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3 ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6 Dynatronics Receives 180-Day NASDAQ Extension 2 Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 1 Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 2 Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 3 Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 1 Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 2 Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 3 Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 4 Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 5 Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 1 Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 2

[0] ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)[0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer [0] Dynatronics Receives 180-Day NASDAQ Extension